Neurofibromatosis Type 1 | CHOP Research Institute

Neurofibromatosis Type 1

In this study we are seeking to learn how different eye tests and devices can help understand vision in patients with NF1, including how vision loss might show up on different eye imaging devices that measure the nerves or the blood vessels of the eye.

Published on
Oct 27, 2021
A rare disease hack-a-thon leads to an unusual collaboration between D3b’s bioinformaticians, including Adam Resnick, PhD, and American Airlines’ software engineers.
Published on
Feb 26, 2021
Data from a phase-2 study show that cabozantinib effectively treats plexiform neurofibromas in patients with neurofibromatosis type 1.

Dr. Shah's clinical research interests are focused in the areas of neurofibromatosis type 1 and retinoblastoma. These studies range from translational studies to clinical trials of novel therapeutics to international consortiums studying long-term effects of therapy.

shahac [at]